Ranbaxy Laboratories Ltd

Generic pharma company Ranbaxy (BSE: 500359), one of India’s largest drugmakers which is in the process of being acquired by Sun Pharma, is considering establishing production in Russia during the next several years, according to recent statements of Denis Manturov, Russia’s Minister of Industry and Trade.

Financial details of the project are not disclosed, however, according to some sources close to the project, the value of investments may reach $200 million.

It is planned that the plant will focus on the production of a wide range of Ranbaxy drugs, which are currently imported to Russia from abroad. Among these drugs are expected to be TSifran, Zanotsin antibiotics, as well as Ketanov and other analgesics.

In addition, there is a possibility of establishing production of drugs for the treatment of diseases in the field of gastroenterology, cardiovascular and metabolism.

15 December 2014

Investor profile

Ranbaxy Laboratories Ltd

Gurgaon, India

Company's website: https://www.ranbaxy.com

T: +91 12 4413 5000

Public company (BSE: 500359)

Contact: Mr Arun Sawhney, Chief Executive Officer

Ranbaxy Laboratories Ltd, India's largest pharmaceutical company, manufactures and markets branded generic pharmaceuticals and active pharmaceutical ingredients.